205 results about "Lipoprotein cholesterol" patented technology

Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes. A method for assessing diabetes includes identifying the presence of diabetic dyslipidemia based on the values of predetermined NMR measured lipoprotein constituents.

The invention discloses a composition of probiotic fermented horseradish tree leaves as well as a preparation method and application of the composition. The preparation method comprises the following steps: crushing and immersing horseradish tree leaves; adding glucose, peptone, yeast extract, yeast powder and inorganic salt into an immersing solution; extracting at a high pressure; and after carrying out probiotic fermentation and centrifuging, adding polydextrose and fructo-oligosaccharide syrup and sterilizing to obtain the composition of the probiotic fermented horseradish tree leaves. The composition can be used for preparing health products, foods and beverages capable of lowering blood fat and improving a sleeping function. An experiment shows that the composition of the probiotic fermented horseradish tree leaves can be used for reducing the contents of total cholesterol (TC) and triglyceride (TG) in blood serum, and improving the content of high density lipoprotein cholesterol (HDL-C) in the blood serum; the composition of the probiotic fermented horseradish tree leaves, disclosed by the invention, has a function of lowering a blood fat level.

The invention provides an oligosaccharide oat beverage capable of treating hyperlipoidemia and hyperglycemia and improving gastrointestinal tract function and a manufacturing method thereof by hydrolysis of three enzymes and fine grinding. The manufacturing method comprises the following steps: carrying out fine grinding on the oat meal to obtain the powder of which the average particle size is less than about 100 mu m, dissolving the oat powder in water to form oat slurry, and adding alpha-amylase, beta-amylase and trans-glucosidase to carry out enzyme treatment, thereby obtaining the oat beverage with rich functional components. The oligosaccharide oat beverage integrally reserves oat beta-dextran, and also contains oligo-isomaltose component of which the content is higher than that in common oat products. The manufacturing method can integrally reserve the nutritional components of the whole oat grains and omit the filter operation, thereby being beneficial to increasing the utilization ratio of raw materials; and the method is completed under the conditions of fermentation and sterilization in the optimal short time, thereby avoiding the possibility of rancidity of oat slurry in the processing procedure. When the oligosaccharide oat beverage is used for human testing for assessing physiologic effect, the test proves that the oligosaccharide oat beverage can lower the total cholesterol, low-density lipoprotein cholesterol, triglyceride and fasting blood-glucose value in blood. The oligosaccharide oat beverage tastes savoury, thick and smooth like milk, and maintains the natural flavor of oat; and thus, the invention changes the traditional way for eating oat, greatly raises the nutrition health-care value of oat processed products, and has the potentials of preventing and treating hyperlipoidemia, hyperglycemia and other life-style related diseases and improving the gastrointestinal tract function.

The invention relates to a kit for measuring high-density lipoprotein cholesterol. The kit comprises a first reagent and a second reagent, wherein the first reagent comprises a surface active agent I used for inhibiting the dissolution of non-high-density lipoprotein (NHDL), and a surface active agent II used for dissolving high-density lipoprotein (HDL); after the surface active agent I is mixed with the surface active agent II, the value of hydrophile-lipophile balance (HLB) is within the range of 13-14; the volume ratio of the surface active agent I to the surface active agent II in the first reagent is (1:30)-(1:1). Due to the synergistic effect of components, the stability of the kit is improved, and the HDL can be specifically released; furthermore, the dissociation of the NHDL can be specifically masked and inhibited, the interference of other components in serum can be eliminated, and the accuracy of measurement is guaranteed.

A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is administered over a period of time, whereby in the levels of some or all of blood glucose, insulin, total cholesterol, LDL cholesterol, triglyceride, creatine kinase (CK), creatine kinase-MB (CK-MB), Hb-A1c, lipoprotein (a), SGOT and SGPT fall back within the normal range or are significantly reduced.

A reagent for the content of the high density lipoprotein cholesterol in the quantitative determining serum sample, consists of the reagent I and reagent II that places respectively, the reagent I contains the heteropolymer anion compound, the divalency cation salt and the decentralized surfactants; the reagent II contains the styrylphenol polyoxyethylene ether. The invention provides a reagent box with the reagent I and the reagent II, and a method for determining the high density lipoprotein cholesterol content.

The invention relates to an in-vitro diagnostic reagent for a homogeneous method of low-density lipoprotein cholesterol (LDL-C) of serum, wherein the in-vitro diagnostic reagent is capable of being widely applied to the technical field of medicine and biochemistry and is characterized in that the in-vitro diagnosis is carried out by means of a method comprising the following steps of: step one, selectively cracking chyle particles (CM), very low density lipoprotein cholesterol (VLDL-C) and high density lipoprotein cholesterol (HDL-C) within the serum by using a group of surfactant comprising trimethyl-beta-cyclodextrin, ethylene oxide octadecyl amine, poloxamer F88 and Brij-58, then generating hydrogen peroxide (H2O2) during the catalytic reaction of cholesterol esterase (COE) and cholesterol oxidase (COD), and then discomposing the H2O2 by means of a chemiluminescence clearing system of hydrogen peroxide, wherein the LDL-C particles within the serum are still kept perfectly at the moment; step two, reacting the LDL-C by catalyzing with the COE and the COD under the effect of TritonX-100 so as to generate H202, then promoting a chemiluminescence quantitative system to produce chemiluminescence by catalyzing the H2O2 with POD, and quantitating the LDL-C after measuring luminous intensity. The measuring reagent provided by the invention has the advantages that the sensitivity is high, the capacity of resisting disturbance is strong, the purpose for detecting the LDL-C of serum in batch is realized on a microporous plate chemiluminescence apparatus by measuring chemiluminescence intensity, and the reagent is suitable for the application in clinical laboratory.

A 2,3,5,4'-tetrahydroxy distyrene-2-O-beta-D-glucoside used for hypoglycemic medicine is prepared from the decoction of fleece flower root through extracting, separating and purifying. It can suppress the increasement of serum cholesterol, decrease low-density serum lipoprotein cholesterol and improve activity of liver esterase.

A reagent for detecting low - density lipoprotein cholesterol is composed of buffer solution, stabilizer, chromogen, high affinity enzyme compound, surface active agent being added in reagent as the ratio of 10 - 50 g / L, catalyst, antiseptic and anti - interference substance. Its preparing method includes activating compound, dissolving enzyme, mixing, reacting and proportioning.

A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

The invention discloses compound nutritional noodles and a preparation method thereof. The compound nutritional noodles are prepared by taking perilla frutescens, se-enriched mushrooms and buckwheat as main raw materials, wherein the organic selenium content of the compound nutritional noodles reaches 200 mu g / kg, and the alpha linolenic acid content of the compound nutritional noodles reaches 2%. The preparation method comprises the steps of: (1) preparation of se-enriched mushroom powder or se-enriched malt powder; (2) preparation of perilla frutescens pulp; (3) preparation of buckwheat powder; (4) determination of a formula of the nutritional noodles; and (5) preparation of the noodles. Research proves that due to the reasonable collocation of the perilla frutescens pulp, the se-enriched mushroom powder or the se-enriched malt powder and the buckwheat powder, strong nutrition and health care functions can be brought into play in the aspects of regulating the fat metabolism, enhancing the immunoregulation, reducing the high blood fat and low-density lipoprotein cholesterol, eliminating lead and detoxifying, protecting the liver and heart and blood vessels, and the like. Therefore, the compound nutritional noodles disclosed by the invention have the function of compound nutrition, increase the diet varieties, and can promote the health of people. The compound nutritional noodles are suitable for adults and children to eat.

The invention discloses an application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and / or medicines. The lactobacillus rhamnosus CCFM1060 can tolerate thegastrointestinal environment of the human body, significantly improve fasting blood glucose rise and abnormal oral glucose tolerance of type 2 diabetics caused by high fat diet and STZ injection, reduce the area under the curve during glucose tolerance drug administration, and relieve insulin resistance; remarkably improve the increase of total cholesterol content and the increase of low-density lipoprotein cholesterol in serum of type 2 diabetics caused by high-fat diet and STZ injection; obviously relieve the inflammatory state of the liver; and significantly reduce pancreatic and liver pathological injuries caused by high-fat diet and STZ injection. The lactobacillus rhamnosus CCFM1060 has relatively strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving the toxicity of the PFOA.

The invention provides a reagent for directly and quantitatively determining low-density lipoprotein cholesterol (LDL-C) in human serum in a homogeneous system by an enzymatic method. The reagent is suitable for automatically and quantitatively determining the LDL-C by an automatic biochemical analyzer. The reagent consists of a solution type reagent 1 and a solution type reagent 2 which are placed separately, wherein the reagent 1 contains cholesterol esterase, cholesterol oxidase, 4-amino-antipyrine, catalase, surfactant, a buffering agent and a stabilizing agent; and the reagent 2 comprises peroxidase, a color-developing agent, the other surfactant, a stabilizing agent and a buffering agent. The invention also provides a method for directly determining the content of the LEDL-C in the homogeneous system without pre-treating a serum sample, and a kit which specifically uses the method in a clinical laboratory and in which the reagent 1 and the reagent 2 are accommodated.

The invention discloses a method and reagent for detecting small and dense low-density lipoprotein cholesterol (sdLDL-C) in a sample. The method is characterized by comprising the steps of (1) eliminating cholesterol, except the sdLDL-C, in lipoproteins in the sample first in the presence of cholesterol esterase and an ion selective agent; and (2) conducting quantitative detection on remaining sdLDL-C obtained after treatment in step (1). The ion selective agent is used to selectively eliminate lipoproteins other than the sdLDL-C, so as to detect the sdLDL-C.

A lipid-lowering tea and a production method relate to the production process of bagged tea. The invention mainly comprises raw hawthorns, cassia seeds, lotus leaves and black tea. The invention can obviously inhibit the increase of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and atherosclerosis index (CAI) of serum, improve the high-density lipoprotein cholesterol (HDL-C) and anti-atherogenic index (AI), prevent fatty liver degeneration, slow and inhibit the formation of atherosclerotic plaque. The tea is of food class, which ensures the taste and has the specific effect; long-term tea drinking causes no toxic side effects; besides, the lipid-lowering tea is convenient and can be used in daily life, working, tourism and leisure time, and the user can enjoy health-care in tea drinking.

The invention relates to fish oil and linseed oil soft capsules and a preparation method thereof. The soft capsules mainly comprise the following raw materials in parts by weight: 30 to 80 parts of fish oil, 20 to 60 parts of linseed oil, and 5 to 20 parts of vitamin E; and the fish oil and linseed oil soft capsules are prepared through the steps of preparing an inclusion, making capsule bodies, preparing capsules and the like. Compared with the prior art, the soft capsules have the advantages that the fish oil contains polyunsaturated fatty acids such as docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), so that low-density lipoprotein cholesterol in blood can be effectively reduced, the content of neutral fat is reduced, and high-density lipoprotein cholesterol is increased; and alpha-linolenic acid can promote the discharge of cholesterol, inhibit the synthesis of endogenous cholesterol and raise high-density lipoprotein, so that the effect of reducing blood fat is achieved.

The invention discloses application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and / or medicines. The bifidobacterium adolescentis CCFM1061 can be rapidly colonized in the intestinal tracts, can remarkably improve fasting blood glucose and oral glucose tolerance of type 2 diabetes induced by STZ and high-fat diet and decrease the area under a curvewhen glucose tolerance is reduced, can remarkably alleviate the increase of total cholesterol and the decrease of high-density lipoprotein cholesterol in serum of the type 2 diabetes caused by STZ and high-fat diet, can remarkably alleviate the insulin resistance of the type 2 diabetes, can remarkably improve the level of inflammation in liver tissues of the type 2 diabetes, and can remarkably alleviate the pathological damage of the pancreas, liver and other tissues of the type 2 diabetes. In addition, the bifidobacterium adolescentis CCFM1061 has strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving PFOA toxicity.

The invention discloses a blood-glucose-lowering traditional Chinese medicine composition as well as a preparation method and application. Active components of the blood-glucose-lowering traditional Chinese medicine composition are prepared from a group A and a group B through gradient extraction of 70 percent to 30 percent alcohol-water solution or / and water, wherein the group A is prepared from the following components in parts by weight: 20 to 30 parts of folium mori, 10 to 20 parts of bitter gourds and 10 to 20 parts of radix puerariae; the group B comprises 5 to 15 parts of rhizoma dioscoreae by weight. Pharmaceutically acceptable auxiliary materials are added into the active components to prepare oral preparations including oral solutions, granules, tablets, hard capsules, soft capsules, pills and the like according to a conventional method. A pharmacodynamics test result shows that the blood-glucose-lowering traditional Chinese medicine composition can be used for remarkably lowering blood glucose, glycated hemoglobin (GHb) of experiment rats with type 2 diabetes mellitus and improving oxidative stress indexes, and also has a remarkable blood lipid regulation function and can be used for raising HDL-C (High Density Lipoprotein-Cholesterol) and lowering TC (Total Cholesterol), TG (Triglyceride) and LDL-C (Low-Density Lipoprotein Cholesterol). The active components of the traditional Chinese medicine composition are matched with rice and flour and can be processed into health foods capable of preventing and treating diabetes mellitus, such as porridge, noodles, bread and biscuits.

This invention provides a process for extracting the flavonoid and alkaloid components from lotus leaf and provides a method for the reduction of body weight, total cholesterol (TC), low density lipoprotein (LDL) cholesterol, and triglycerides (TG). It also provides a method for increasing high density lipoprotein (HDL) cholesterol and the prevention of coronary heart disease (CHD). There are 10% to 80% flavones and 10% to 80% alkaloids in the lotus leaf extract powder of this invention. This process produces an improved standardized raw material that may be utilized as a single dietary supplement, food additive, or medicine and it may be added to other plant extracts, nutraceuticals, or pharmaceuticals.

The invention discloses a high-performance small and dense low-density lipoprotein cholesterol detection kit. The kit comprises the following raw materials in parts by weight; a reagent A: 90 to 110 mmol / L of a Good's buffer solution; 1-3 ku / L of cholesterol esterase, 1-2 ku / L of cholesterol oxidase, 0.7-0.9 ku / L of phospholipase, 400-600 ku / L of catalase, and 1-3 mmol / L N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium salt (TOOS); and a reagent B: 90-110 mmol / L of the Good's buffer solution, 2-3 ku / L of peroxidase, 3-5 mmol / L of 4-aminoantipyrine and 0.04-0.06% of sodium azide. Theinvention relates to the technical field of lipoprotein cholesterol detection, and discloses the high-performance small and dense low-density lipoprotein cholesterol detection kit. The non-sdLDL-C components are removed through cholesterol lipase, cholesterol oxidase, phospholipase and catalase; the interference of other lipoprotein cholesterol on the detection process is avoided, the capacity ofthe small and dense low-density lipoprotein cholesterol in serum can be directly determined by using a full-automatic biochemical analyzer, and the kit is suitable for the requirements of clinical andlaboratory on the determination of the content of the small and dense low-density lipoprotein cholesterol.

The invention discloses a kit for detecting small and dense low-density lipoprotein cholesterin. The kit is characterized by comprising polyoxyethylene fatty acid ester, cholesterol esterase, cholesterol oxidase, dodecyl polypeptide and triton X-100, wherein the small and dense low-density lipoprotein cholesterin in a serum sample is protected under the action of the polyoxyethylene fatty acid ester, reaction of the small and dense low-density lipoprotein cholesterin with the cholesterol esterase and the cholesterol oxidase is inhibited to a certain extent, and the other lipoprotein cholesterols react with the cholesterol esterase and the cholesterol oxidase under the action of the dodecyl polypeptide to be eliminated; and the triton X-100 reacts with the remaining small and dense low-density lipoprotein cholesterin to detect the content thereof. The kit can be used for quickly and conveniently detecting sdLDL-C in the serum sample. The reagent formula is simple and easy to prepare and low in cost, large-scale industrial preparation can be carried out, and meanwhile, the kit is capable of efficiently, accurately and specifically detecting the small and dense low-density lipoprotein cholesterin in the sample.

The invention provides application of PCSK9-targeted microRNA or a drug composition containing the same in preparing drug for inhibiting PCSK9 protein level. In addition, the invention further relatesto a drug composition for treating low-density lipoprotein cholesterol related metabolic disease. The drug composition comprises (a) drug in effective treatment amount and clinically for treating thelow-density lipoprotein cholesterol related metabolic disease and (b) PCSK9-targeted microRNA or the drug composition containing the same in effective treatment amount. Experiments verify that 31 types of microRNA can inhibit PCSK9 protein level in liver cells or liver cell culture liquid, thereby being capable of lowering level of LDLC so as to treat the LDLC related metabolic disease.

The invention provides an efficient and specific small and compact low-density lipoprotein cholesterol detection kit. The kit is a liquid dual reagent and consists of a reagent R1 and a reagent R2 according to the volume ratio of 3: 1. A polymer combination including 3-benzyloxy phenyl ether, polyoxyethylene alkyl ether and PEG800 in the efficient and specific small and compact low-density lipoprotein cholesterol detection kit serves as an important composition in the reagent R1 to fully eliminate influences of lipoprotein cholesterol except for sdLDL-C in a to-be-detected sample to sdLDL-C detection well; and moreover, in the reagent R2, by addition of a denaturant Triton X-100, protected sdLDL-C in the to-be-detected sample is released, thus, only sdLDL-C is detected efficiently and specifically, and accuracy of a detecting result is ensured.

The invention discloses a diagnosis and / or typing marker for the PCOS (polycystic ovarian syndrome) and an application of the preparation reagent and particularly relates to an application of cyclic guanosine monophosphate, dehydroepiandrosterone sulfate, palm sphingomyelin combined HDL-C (high-density lipoprotein cholesterol) and the left follicle number as the diagnosis and / or typing marker for the PCOS. Compared with existing PCOS diagnosis clinical indexes, the marker can realize the effect of distinguishing a PCOS subgroup I and a PCOS subgroup II through combined diagnosis of cyclic guanosine monophosphate, dehydroepiandrosterone sulfate and palm sphingomyelin. In combination of combined diagnosis of HDL-C (high-density lipoprotein cholesterol) and the left follicle number, the very high diagnosis accuracy is realized for a normal group, the PCOS subgroup I and the PCOS subgroup II, and accurate and effective index systems are provided for clinical disease diagnosis.

The invention provides a lipoprotein cholesterol determination reagent and a kit, belonging to the technical field of biochemical detection. The reagent comprises poly-alpha-olefin, cholesterol oxidase and reaction promoter, and further comprises cholesterol esterase, peroxidase, catalase, catalase inhibitor, surface active agent, emulsifier, polyanion, divalent cation, stabilizer, anti-interference agent, color developing agent and preservative. The reagent and the kit provided by the invention can be used for full-automatic biochemical analyzer detection, are simple and convenient to operate, can improve detection efficiency and accuracy and can reduce detection cost.

The invention relates to an siRNA for inhibiting expression of an FABP4 gene. A sequence of the siRNA is shown as follows: sense strand: 5'-CGACCACAAUAAAGAGAAA-3' antisense strand: 5'-UUUCUCUUUAUUGUGGUCG-3'. According to the siRNA disclosed by the invention, three pairs of siRNA sequences are designed, aiming at the FABP4 gene, and an siRNA which is capable of effectively down regulating expression of a target gene is screened by virtue of a cell transfection test; according to the screened siRNA-368 sequence, a corresponding lentivirus expression carrier is constructed; and verified by a test of transfecting an obese mouse with high fat and inhibiting expression of mouse visceral fat tissue FABP4 gene, the screened siRNA is capable of effectively inhibiting expression of the mouse FABP4 gene and lowering weight, glycosylated hemoglobin, total cholesterol and level of low-density lipoprotein cholesterol of the obese mouse with high fat.

The invention relates to an antrodia camphorate composition. The composition is prepared from the following components in parts by weight: 100-135 parts of antrodia camphorate mycelia, 12-18 parts of coenzyme Q10, 15-30 parts of gynostemma pentaphylla, 20-35 parts of pseudo-ginseng, 5-12 parts of American ginseng, 3-6 parts of wolfberry fruits and 20-40 parts of olive extract. The antrodia camphorate composition can be used for lowering the contents of total blood serum cholesterol, low-density lipoprotein cholesterol and triglyceride and improving the content of high-density lipoprotein cholesterol; the liver damage can be reduced and the liver function can be improved; and the antrodia camphorate composition has the effects of activating blood and removing blood stasis, lowering blood pressure and preventing cardiovascular and cerebrovascular events, and also has the effects of lowering blood glucose, improving the immunity and resisting tumors.

The invention discloses a hydroxytyrosol-containing blood fat-reducing composition which is characterized by being prepared from hydroxytyrosol, hyaluronic acid, arginine and citrulline according to a certain ratio. The composition can increase the content of high-density lipoprotein cholesterol in blood and reduce the content of low-density lipoprotein cholesterol. The invention further provides application of the hydroxytyrosol composition in preparation of a medicine and a health product which have blood fat reducing and oxidization resisting functions, and application of the hydroxytyrosol composition in preparation of a medicine and a health product which can assist in preventing and treating cardiovascular and cerebrovascular diseases.

The invention relates to a test strip for detecting low-density lipoprotein cholesterol in serum. The test strip includes a dry chemical reaction chip, the dry chemical reaction chip is prepared by soaking a reagent pad in a chemical reagent and then drying the reagent pad, and the chemical reagent is prepared from cholesterol esterase, cholesterol oxidase, peroxidase, metal salt, a color developer, polyoxyethylene ether and an ethylene oxide-propylene oxide copolymer having preferable concentrations according to a preferable ratio. The test strip has the advantages of low cost, easiness in preparation and obtaining, quickness in reaction and convenience in operation.